Yahoo Finance Exploring Three High Growth Tech Stocks in the United States
The market has climbed 1.9% in the last 7 days and is up 33% over the past 12 months, with earnings expected to grow by 15% per annum over the next few years. In this favorable environment, identifying high growth tech stocks that align with these trends can be crucial for investors seeking robust returns.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
Super Micro Computer | 20.86% | 27.98% | ★★★★★★ |
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Sarepta Therapeutics | 23.58% | 44.12% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Ardelyx | 27.46% | 66.34% | ★★★★★★ |
Amicus Therapeutics | 20.32% | 62.37% | ★★★★★★ |
Clene | 71.89% | 60.05% | ★★★★★★ |
Travere Therapeutics | 26.68% | 68.80% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Rapid7
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Rapid7, Inc. provides cybersecurity solutions under the Rapid7, Nexpose, and Metasploit brand names and has a market cap of $2.24 billion.
Operations: Security Software & Services is the primary revenue stream, generating $817.20 million. Rapid7 focuses on cybersecurity solutions through its well-known brands.
Rapid7's recent pivot towards innovative security solutions like Vector Command underscores its strategic response to the expanding attack surfaces in IT. This service, integrating continuous Red Teaming with attack surface assessments, addresses critical vulnerabilities in real-time—a crucial advancement as digital assets sprawl across cloud and SaaS platforms. Financially, Rapid7 has shown resilience with a notable turnaround from a net loss of $66.78 million last year to a net income of $8.2 million this quarter, reflecting an earnings surge by 59.3%. The firm's commitment to R&D is evident from its launch of the Command Platform, enhancing cybersecurity measures for enterprises grappling with complex digital ecosystems. These strategic moves not only bolster Rapid7’s product offerings but also solidify its position in a competitive landscape where persistent innovation is key to attracting and retaining top-tier clients.
Click here to discover the nuances of Rapid7 with our detailed analytical health report.
Gain insights into Rapid7's historical performance by reviewing our past performance report.
Humacyte
Simply Wall St Growth Rating: ★★★★★☆
Overview: Humacyte, Inc. develops and manufactures off-the-shelf, implantable, and bioengineered human tissues for treating various diseases and conditions across multiple therapeutic areas, with a market cap of $624.21 million.
Operations: Humacyte specializes in creating bioengineered human tissues for various medical applications. The company focuses on developing off-the-shelf, implantable solutions to treat a wide range of diseases and conditions across different therapeutic areas.
Humacyte, Inc., while navigating the challenging biotech landscape marked by a volatile share price and ongoing unprofitability, stands out with its innovative BioVascular Pancreas (BVP) product. This cutting-edge solution, aimed at revolutionizing type 1 diabetes treatment, recently gained traction through a newly granted U.S. Patent and positive preclinical results showing potential in insulin delivery using acellular tissue engineered vessels. Despite a significant net loss of $56.66 million in Q2 2024, Humacyte's commitment to R&D is underscored by its recent $50 million follow-on equity offering, which could fuel further development and clinical trials. With revenue growth forecasted at an impressive rate of 68.2% per year and earnings expected to surge by 66.08% annually, the company's future seems promising as it moves towards market growth above average predictions for the next three years.
Unlock comprehensive insights into our analysis of Humacyte stock in this health report.
Evaluate Humacyte's historical performance by accessing our past performance report.
AbbVie
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide with a market cap of $342.37 billion.
Operations: AbbVie generates its revenue primarily from pharmaceutical products, which contributed $55 billion. The company's net profit margin stands at 23.5%.
AbbVie's recent strategic maneuvers, including a notable collaboration with Ripple Therapeutics to develop a biodegradable implant for glaucoma treatment, underscore its innovative approach in the pharmaceutical sector. This partnership not only leverages AbbVie’s ocular expertise but also integrates Ripple's cutting-edge drug delivery technology, potentially enhancing patient compliance and outcomes in eye care. Additionally, the company's R&D commitment is reflected in its substantial investment, with R&D expenses reaching 25.3% of its revenue last year. Such initiatives are pivotal as AbbVie navigates through the competitive landscape marked by rapid technological advancements and evolving healthcare needs.
Take a closer look at AbbVie's potential here in our health report.
Gain insights into AbbVie's past trends and performance with our Past report.
Where To Now?
Investigate our full lineup of 251 US High Growth Tech and AI Stocks right here.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Looking For Alternative Opportunities?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:RPD NasdaqGS:HUMA and NYSE:ABBV.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
